CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)
- Citation:
- J Clin Oncol vol 30 (18 suppl) abstr CRA1002
- Meeting Instance:
- ASCO 2012
- Year:
- 2012
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2128
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- H. S. Rugo W. T. Barry A. Moreno-Aspitia A. P. Lyss C. Cirrincione E. L. Mayer M. Naughton R. M. Layman L. A. Carey R. A. Somer E. A. Perez C. Hudis E. P. Winer
- Networks:
- Study
- CALGB-40502
- Multiple Studies, or Legacy Studies in Alliance Study:
- NCCTG-N063H
- Phases:
- 3, 3
- Keywords: